Drug survival in cyclosporine treatment for moderate to severe atopic dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP)
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Couselo Rodríguez, Carmen
- dc.contributor.author Giménez Arnau, Anna Maria
- dc.contributor.author Curto Barredo, Laia
- dc.contributor.author Flórez, Ángeles
- dc.date.accessioned 2024-09-25T05:57:51Z
- dc.date.available 2024-09-25T05:57:51Z
- dc.date.issued 2024
- dc.description Article disponible en castellà: http://hdl.handle.net/10230/61211
- dc.description.abstract Background: The past 5 years have seen a proliferation of new treatments for atopic dermatitis (AD). We analyzed recent drug survival data for cyclosporine in this setting. Because the Spanish National Healthcare system requires patients with AD to be treated with cyclosporine before they can be prescribed other systemic treatments, drug survival for cyclosporine may be shorter than in other diseases. Material and method: Multicenter, observational, prospective cohort study using data from the Spanish Atopic Dermatitis Registry (BIOBADATOP). Data from the Spanish Registry of Systemic Treatments in Psoriasis (BIOBADADERM) were used to create a comparison cohort. Results: We analyzed data for 130 patients with AD treated with cyclosporine (median drug survival, 1 year). Median cyclosporine survival in the psoriasis comparison group (150 patients) was 0.37 years. Drug survival was significantly longer in AD than in psoriasis (P<.001). Conclusion: Drug survival of cyclosporine in the BIOBADATOP registry is similar to that described in other series of patients with AD and longer than that observed in the BIOBADADERM psoriasis registry.
- dc.format.mimetype application/pdf
- dc.identifier.citation Couselo-Rodríguez C, Batalla A, Carrascosa JM, Chicharro P, González-Quesada A, de la Cueva P, et al. Drug survival in cyclosporine treatment for moderate to severe atopic dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP). Actas Dermosifiliogr. 2024 Apr;115(4):t341-t6. DOI: 10.1016/j.ad.2023.07.028
- dc.identifier.doi http://dx.doi.org/10.1016/j.ad.2023.07.028
- dc.identifier.issn 0001-7310
- dc.identifier.uri http://hdl.handle.net/10230/61210
- dc.language.iso eng
- dc.publisher Elsevier
- dc.relation.ispartof Actas Dermosifiliogr. 2024 Apr;115(4):t341-t6
- dc.rights © 2023 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.subject.keyword Atopic dermatitis
- dc.subject.keyword Cyclosporine
- dc.subject.keyword Survival analysis
- dc.title Drug survival in cyclosporine treatment for moderate to severe atopic dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP)
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion